Founded in 2007 by Chris Procyshyn and Ross Gold, Vanrx makes robotic aseptic filling machines to fill vials, syringes, and cartridges with reduced risk and increased speed to patients. Vanrx counts leading biopharmaceutical companies as its customers.
Vanrx’s flagship products are the SA25 Aseptic Filling Workcell and Microcell Vial Filler, which automate aseptic filling using robotics within closed, gloveless isolators. These standardized, flexible systems provide a fast and certain path to filling capacity as the final step in manufacturing clinical and commercial biopharmaceuticals.
“We created Vanrx to enable every company to manufacture safe and cost-effective injectable therapies. Our own experience told us that new technologies are needed to support next-generation therapies and personalized medicine,” Procyshyn, Vanrx co-founder and CEO, said regarding the announcement.
“Cytiva is a perfect home for what we have built. Thanks to their reach, we will be able to help our current and future customers change the lives of even more patients around the world.”
Vanrx currently has 120 employees, all of whom have been offered roles with Cytiva.